Sphingomyelinase mutants and their application in the detection of sdLDL cholesterol

By developing five sphingomyelinase mutants, the activity of sphingomyelinase was improved, and the problem of low sdLDL removal efficiency in the prior art was solved, and more efficient sdLDL cholesterol detection was achieved.

CN116790552BActive Publication Date: 2024-11-01BODING BIOENGINEERING (BEIJING) CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202211502054.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-11-28
Publication Date
2024-11-01
Estimated Expiration
2042-11-28

AI Technical Summary

Technical Problem

In the prior art, the clearance rate and efficiency of sphingomyelinase for LDL except small and dense low density LDL (sdLDL) is low, which affects the accuracy of sdLDL cholesterol content determination.

Method used

Five sphingomyelinase mutants were developed, including D118Q, N122D, N333E, Q376Y and MUT, to improve the activity of sphingomyelinase through genetic engineering technology and enhance its clearance of sdLDL for sdLDL cholesterol detection.

Benefits of technology

The activity of the mutant is increased by about 2 to 3 times, improving the efficiency and accuracy of sdLDL cholesterol detection, reducing vitality units used, and higher detection efficiency.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0003966624560000081
    Figure BDA0003966624560000081
  • Figure HDA0003966624570000011
    Figure HDA0003966624570000011
  • Figure HDA0003966624570000012
    Figure HDA0003966624570000012
Patent Text Reader

Abstract

The present invention discloses sphingomyelinase mutants and their application in sdLDL cholesterol detection, belonging to the technical field of lipid content detection. Specifically, it relates to five sphingomyelinase mutants: sphingomyelinase mutant D118Q, sphingomyelinase mutant N122D, sphingomyelinase mutant N333E, sphingomyelinase mutant Q376Y, sphingomyelinase mutant MUT, and their amino acid sequences are shown in SEQ ID NOs: 2 to 6, respectively. Application of the sphingomyelinase mutants in sdLDL cholesterol detection. The present invention also discloses encoding genes of five sphingomyelinase mutants, and their nucleotide sequences are shown in SEQ ID NOs: 8 to 12, respectively. Compared with wild-type sphingomyelinase, the five sphingomyelinase mutants of the present invention have higher activity, which is increased by 2 to 3 times. When used for sdLDL cholesterol detection, fewer activity units are used and the efficiency is higher.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to a sphingomyelinase mutant and application thereof in sdLDL cholesterol detection, belonging to the technical field of lipid content detection. Background Art

[0002] Cholesterol is a derivative of cyclopentane polyhydrophenanthrene, which is widely present in animals, especially in the brain and nerve tissue. Cholesterol is an important indicator of clinical biochemical examination. Under normal circumstances, the cholesterol synthesized in the liver and taken from food will be converted into steroid hormones or become a component of cell membranes, and the cholesterol concentration in the blood will remain constant. When the liver is seriously diseased, the cholesterol concentration will decrease. In patients with jaundice obstruction and nephrotic syndrome, the cholesterol concentration tends to increase.

[0003] Cholesterol exists in lipoproteins in the blood, and its existence forms include high-density lipoprotein (HDL), low-density lipoprotein (LDL), and very low-density lipoprotein (L LDL). HDL helps to remove cholesterol from cells, while LDL plays a major role in the cholesterol transport in the blood and is a risk factor for arteriosclerosis. Small dense low-density LDL (sdLDL) is known, which has a particularly small particle size in LDL and a higher density than standard LDL, and has an atherogenic ability several times higher than normal LDL. The increase of sdLDL is one of the main risk factors for arteriosclerosis. Therefore, it is very important to perform a graded determination of such sdLDL in clinical practice.

[0004] At present, enzymatic diagnostic reagents are mainly used clinically to detect sdLDL cholesterol content, and sphingomyelinase (SPC) is the core component of this type of diagnostic reagent. Sphingomyelinase is a very important hydrolase in the sphingomyelin metabolic pathway and is closely related to the synthesis of ceramide. Its reaction rate increase for LDL other than sdLDL is greater than that for sdLDL. Therefore, sphingomyelinase is first used to remove cholesterol from LDL other than sdLDL and exclude it from the reaction system, and then the cholesterol in sdLDL is measured. Optimizing the activity of sphingomyelinase is of great significance in the determination of sdLDL cholesterol content.

[0005] Existing test methods show that the clearance rate and efficiency of sphingomyelinase for LDL other than sdLDL still need to be improved. Therefore, finding and preparing sphingomyelinase mutants with higher reactivity is the key to improving the method of measuring sdLDL cholesterol content. Summary of the invention

[0006] In view of the above prior art, the present invention provides five sphingomyelinase mutants and their application in sdLDL cholesterol detection.

[0007] The present invention is achieved through the following technical solutions:

[0008] The amino acid sequence of the sphingomyelinase mutant D118Q is shown in SEQ ID NO:2.

[0009] The amino acid sequence of the sphingomyelinase mutant N122D is shown in SEQ ID NO:3.

[0010] The amino acid sequence of the sphingomyelinase mutant N333E is shown in SEQ ID NO:4.

[0011] The amino acid sequence of the sphingomyelinase mutant Q376Y is shown in SEQ ID NO:5.

[0012] The sphingomyelinase mutant MUT, i.e., a mutant with four simultaneous mutations, has an amino acid sequence as shown in SEQ ID NO: 6. SEQ ID NO: 1:

[0013] 1MSGSRPGCHR RDHQVHRIRT ELEKHVALDL PRLPRLPRLP RAALVVTGTAALLSPAAVGT61AAAAESAAPS LSVMAFNVEQ LPSITELAGT PGSDRRAERR EAAAVVIKRENADVVVLDEA121FNKYAQAMRA MELKEVYPYQ TSLVGEYCSG SGRWTSYEGN CSNSPFVVNGGVTTLLSKYPI181LESHQLVYRN SDSKTSDYKS NKGAALARLS VNGQSVWVAG THLQADEEGSSPVGNTRKVR241LEQLKELRAW ASDKAGGAPV VVAGDFNVEY YTTDPKNGHA PGTGVSGEVAKANEALGGVL301ATPGTTGYTY DMVDNPRARL RDDKDNGYAK YRNRLDYIGY IKGTGTQPSFSDERIVGYDG361LRKGGDPLAE IPSDHQPIVS RVTVGR.

[0014] SEQ ID NO:2: (118Q is in bold and underlined)

[0015] 1MSGSRPGCHR RDHQVHRIRT ELEKHVALDL PRLPRLPRLP RAALVVTGTAALLSPAAVGT61AAAAESAAPS LSVMAFNVEQ LPSITELAGT PGSDRRAERR EAAAVVIKRENADVVVL Q EA121FNKYAQAMRA MELKEVYPYQ TSLVGEYCSG SGRWTSYEGN CSNSPFVVNGGVTLLSKYPI181LESHQLVYRN SDSKTSDYKS NKGAALARLS VNGQSVWVAG THLQADEEGSSPVGNTRKVR241LEQLKELRAW ASDKAGGAPV VVAGDFNVEY YTTDPKNGHA PGTGVSGEVAKANEALGGVL301ATPGTTGYTY DMVDNPRARL RDDKDNGYAK YRNRLDYIGY IKGTGTQPSFSDERIVGYDG361LRKGGDPLAE IPSDHQPIVS RVTVGR。

[0016] SEQ ID NO:3:(122D in bold and underlined)

[0017] 1MSGSRPGCHR RDHQVHRIRT ELEKHVALDL PRLPRLPRLP RAALVVTGTAALLSPAAVGT61AAAAESAAPS LSVMAFNVEQ LPSITELAGT PGSDRRAERR EAAAVVIKRENADVVVLDEA121F D KYAQAMRA MELKEVYPYQ TSLVGEYCSG SGRWTSYEGN CSNSPFVVNGGVTLLSKYPI181LESHQLVYRN SDSKTSDYKS NKGAALARLS VNGQSVWVAG THLQADEEGSSPVGNTRKVR241LEQLKELRAW ASDKAGGAPV VVAGDFNVEY YTTDPKNGHA PGTGVSGEVAKANEALGGVL301ATPGTTGYTY DMVDNPRARL RDDKDNGYAK YRNRLDYIGY IKGTGTQPSFSDERIVGYDG361LRKGGDPLAE IPSDHQPIVS RVTVGR。

[0018] SEQ ID NO:4: (333E is in bold and underlined)

[0019] 1MSGSRPGCHR RDHQVHRIRT ELEKHVALDL PRLPRLPRLP RAALVVTGTA ALLSPAAVGT

[0020] 61AAAAESAAPS LSVMAFNVEQ LPSITELAGT PGSDRRAERR EAAAVVIKRE NADVVVLDEA

[0021] 121FNKYAQAMRA MELKEVYPYQ TSLVGEYCSG SGRWTSYEGN CSNSPFVVNG GVTLLSKYPI

[0022] 181LESHQLVYRN SDSKTSDYKS NKGAALARLS VNGQSVWVAG THLQADEEGS SPVGNTRKVR

[0023] 241LEQLKELRAW ASDKAGGAPV VVAGDFNVEY YTTDPKNGHA PGTGVSGEVA KANEALGGVL

[0024] 301ATPGTTGYTY DMVDNPRARL RDDKDNGYAK YR E RLDYIGY IKGTGTQPSF SDERIVGYDG

[0025] 361LRKGGDPLAE IPSDHQPIVS RVTVGR。

[0026] SEQ ID NO:5: (376Y is in bold and underlined)

[0027] 1MSGSRPGCHR RDHQVHRIRT ELEKHVALDL PRLPRLPRLP RAALVVTGTA ALLSPAAVGT

[0028] 61AAAAESAAPS LSVMAFNVEQ LPSITELAGT PGSDRRAERR EAAAVVIKRE NADVVVLDEA

[0029] 121FNKYAQAMRA MELKEVYPYQ TSLVGEYCSG SGRWTSYEGN CSNSPFVVNG GVTLLSKYPI

[0030] 181LESHQLVYRN SDSKTSDYKS NKGAALARLS VNGQSVWVAG THLQADEEGS SPVGNTRKVR

[0031] 241LEQLKELRAW ASDKAGGAPV VVAGDFNVEY YTTDPKNGHA PGTGVSGEVA KANEALGGVL

[0032] 301ATPGTTGYTY DMVDNPRARL RDDKDNGYAK YRNRLDYIGY IKGTGTQPSF SDERIVGYDG

[0033] 361LRKGGDPLAE IPSDH Y PIVS RVTVGR。

[0034] SEQ ID NO:6: (The mutation sites are indicated in bold and underlined)

[0035] 1MSGSRPGCHR RDHQVHRIRT ELEKHVALDL PRLPRLPRLP RAALVVTGTA ALLSPAAVGT

[0036] 61AAAAESAAPS LSVMAFNVEQ LPSITELAGT PGSDRRAERR EAAAVVIKRE NADVVVL Q EA

[0037] 121F D KYAQAMRA MELKEVYPYQ TSLVGEYCSG SGRWTSYEGN CSNSPFVVNG GVTLLSKYPI

[0038] 81LESHQLVYRN SDSKTSDYKS NKGAALARLS VNGQSVWVAG THLQADEEGS SPVGNTRKVR

[0039] 241LEQLKELRAW ASDKAGGAPV VVAGDFNVEY YTTDPKNGHA PGTGVSGEVA KANEALGGVL

[0040] 301ATPGTTGYTY DMVDNPRARL RDDKDNGYAK YR E RLDYIGY IKGTGTQPSF SDERIVGYDG

[0041] 361LRKGGDPLAE IPSDH Y PIVS RVTVGR.

[0042] The application of the sphingomyelinase mutant in the detection of sdLDL cholesterol. In specific applications, the sample to be detected can be whole blood, plasma, serum or tissue. Furthermore, the plasma specimen used is a sodium citrate anticoagulated plasma sample or a heparin anticoagulated plasma sample.

[0043] The nucleotide sequence of the gene encoding the sphingomyelinase mutant D118Q is shown in SEQ ID NO:8.

[0044] The nucleotide sequence of the gene encoding the sphingomyelinase mutant N122D is shown in SEQ ID NO:9.

[0045] The nucleotide sequence of the gene encoding the sphingomyelinase mutant N333E is shown in SEQ ID NO:10.

[0046] The nucleotide sequence of the gene encoding the sphingomyelinase mutant Q376Y is shown in SEQ ID NO:11.

[0047] The nucleotide sequence of the gene encoding the sphingomyelinase mutant MUT is shown in SEQ ID NO:12.

[0048] The application of the coding gene of the sphingomyelinase mutant in the preparation of the sphingomyelinase mutant.

[0049] Compared with the wild-type sphingomyelinase, the five sphingomyelinase mutants of the present invention have activities of single-point mutants D118Q, N122D, N333E and Q376Y increased by about 2 times, and the activity of MUT increased by about 3 times. When used for sdLDL cholesterol detection in samples, fewer activity units are used and the efficiency is higher.

[0050] Various terms and phrases used herein have the general meanings that are well known to those skilled in the art. BRIEF DESCRIPTION OF THE DRAWINGS

[0051] Figure 1 : Schematic diagram of the activities of five sphingomyelinase mutants and wild-type sphingomyelinase.

[0052] Figure 2 : Schematic diagram of the concentration results of sdLDL cholesterol measured by two methods.

[0053] Figure 3 : Schematic diagram of thermal stability analysis of five sphingomyelinase mutants and wild-type sphingomyelinase.

[0054] Figure 4: Schematic diagram of the stability analysis of five sphingomyelinase mutants and wild-type sphingomyelinase stored at -20°C.

[0055] Figure 5 : Schematic diagram of the stability analysis of five sphingomyelinase mutants and wild-type sphingomyelinase stored at 4°C.

[0056] Figure 6 : Schematic diagram of the stability analysis of five sphingomyelinase mutants and wild-type sphingomyelinase stored at 25°C. DETAILED DESCRIPTION

[0057] The present invention will be further described below in conjunction with the examples. However, the scope of the present invention is not limited to the following examples. Those skilled in the art will appreciate that various changes and modifications may be made to the present invention without departing from the spirit and scope of the present invention.

[0058] The instruments, reagents, materials, etc. involved in the following embodiments, unless otherwise specified, are all conventional instruments, reagents, materials, etc. in the prior art and can be obtained through regular commercial channels. The experimental methods, detection methods, etc. involved in the following embodiments, unless otherwise specified, are all conventional experimental methods, detection methods, etc. in the prior art.

[0059] The sources of the strains, plasmids, enzymes and culture media used in the present invention are as follows: Escherichia coli DH5α, BL21 (DE3), cloning and expression plasmid vector pRSFDuet-1 were purchased from Novagen; DNA high-fidelity polymerase mixture was purchased from Tsingke; restriction endonucleases and DNA ligases were purchased from NEB; Escherichia coli LB culture medium: each liter contains 10 g of Tryptone, 5 g of Yeast extract, 10 g of NaCl, and 50 mg of kanamycin.

[0060] Technical terms

[0061] Phospholipase: A class of enzymes present in organisms that can hydrolyze glycerophospholipids.

[0062] There are many types of phospholipases, which act on the ester bonds at different positions of the phospholipid molecules. The enzymes that act on the ester bonds at positions 1 and 2 are called phospholipase A1 and A2, respectively, to produce lysophospholipids and free fatty acids. The enzyme that acts on the ester bonds between phosphate substituents is called phospholipase C, and the enzyme that acts on the ester bonds between phosphate substituents is called phospholipase D. The enzyme that acts on the ester bond at position 1 of lysophospholipids is called phospholipase B1.

[0063] Sphingomyelinase: The "sphingomyelinase" (EC 3.1.4.12) mentioned in the present invention is obtained by expressing in animal cells or microbial cells using genetic engineering methods. The exogenous expression system includes but is not limited to Escherichia coli expression system, Bacillus subtilis expression system, yeast expression system, insect cell expression system or mammalian cell expression system.

[0064] Example 1 Construction of sphingomyelinase mutant sequences

[0065] The wild-type sphingomyelinase is derived from the genome of Streptomyces sp. A9107 in the genus Streptomyces, and consists of 386 amino acid residues, as shown in SEQ ID NO: 1, and the nucleotide sequence of its encoding gene is shown in SEQ ID NO: 7. Reference: Sogabe, T., et al., Sphingomyelinase C from Streptomyces sp. A9107: unusual primary structure for bacterial sphingomyelinase C J Biosci Bioeng, 2012. 114 (4): p. 398-401.

[0066] The gene encoding sphingomyelinase (nucleotide sequence as shown in SEQ ID NO:7) was synthesized and cloned into the expression vector pRSFDuet-1. Primers were designed and site-directed mutagenesis of the sphingomyelinase gene was performed by PCR. Five gene mutants were finally obtained, namely: D118Q (nucleotide sequence as shown in SEQ ID NO:8), N122D (nucleotide sequence as shown in SEQ ID NO:9), N333E (nucleotide sequence as shown in SEQ ID NO:10), Q376Y (nucleotide sequence as shown in SEQ ID NO:11) and MUT (nucleotide sequence as shown in SEQ ID NO:12). The PCR product was digested with DpnI enzyme, transformed into Escherichia coli E.coli DH5α, screened and sequenced for verification.

[0067] The primers for PCR involved in site-directed mutagenesis are as follows (shown in SEQ ID NOs: 13 to 20).

[0068] D118Q FP-7:

[0069] 5′-gacgtggtggtcctgcaagaggcgttta-3′;

[0070] D118Q RP-8:

[0071] 5′-ttgcaggaccaccacgtctgcgttttca-3′;

[0072] N122D FP-9:

[0073] 5′-ctggatgaggcgtttgacaaatacgc-3′;

[0074] N122D RP-10:

[0075] 5′-caaacgcctcatccaggaccaccacg-3′;

[0076] N333E FP-11:

[0077] 5′-tatgctaagtaccgtgaacgtctggatt-3′;

[0078] N333E RP-12:

[0079] 5′-ttcacggtacttagcataaccgttatct-3′;

[0080] Q376Y FP-13:

[0081] 5′-atcccgtccgatcactatccgatcgtat-3;

[0082] Q376Y RP-14:

[0083] 5′-atagtgatcggacgggatctcggccagc-3′.

[0084] The specific steps are as follows:

[0085] (1) Amplification of D118Q sphingomyelinase DNA fragment

[0086] Primers D118Q FP-7 and D118Q RP-8 were designed to synthesize the sphingomyelinase gene fragment in Streptomyces sp.A9107. This gene fragment was used as a template to amplify a plasmid DNA fragment containing a D118Q mutation site using primers D118Q FP-7 and D118Q RP-8. PCR reaction system: 1.1×PCR mix buffer 20μl, upstream and downstream primers (10μM) 1μl each, template 0.2μl. Reaction conditions: 94℃ heat denaturation for 3min; 94℃ denaturation for 30s, 55℃ annealing for 30s, 72℃ extension for 3min, a total of 30 cycles; 72℃ extension for 5min. Take 2-5 μl of PCR product and run electrophoresis on 0.5×TAE agarose gel to detect the amplification result. After confirming that the band is correct, take 5 μl of PCR product, add 1 μl of 10×Digest buffer and 0.5 μl of DpnI, make up to 10 μl with ddH2O, and react at 37°C for 1 hour.

[0087] (2) Amplification of N122D sphingomyelinase DNA fragment

[0088] Primers N122D FP-9 and N122D RP-10 were designed, and the synthetic sphingomyelinase gene fragment was used as a template to amplify a plasmid DNA fragment containing an N122D mutation site using primers N122D FP-9 and N122D RP-10. Other steps were the same as (1).

[0089] (3) Amplification of the N333E sphingomyelinase DNA fragment

[0090] Primers N333E FP-11 and N333E RP-12 were designed, and the synthetic sphingomyelinase gene fragment was used as a template to amplify a plasmid DNA fragment containing a N333E mutation site using primers N333EFP-11 and N333E RP-12. Other steps were the same as (1).

[0091] (4) Amplification of Q376Y sphingomyelinase DNA fragment

[0092] Primers Q376Y FP-13 and Q376Y RP-14 were designed, and the synthetic sphingomyelinase gene fragment was used as a template to amplify a plasmid DNA fragment containing a Q376Y mutation site. Other steps were the same as (1).

[0093] (5) Amplification of MUT (D118Q / N122D / N333E / Q376Y) sphingomyelinase DNA fragment

[0094] The steps are the same as (1), obtained by sequential mutation.

[0095] (6) Cloning of sphingomyelinase mutant gene fragments

[0096] Take 100 μl of competent cells E. coli DH5α in a 1.5 ml centrifuge tube, add 10 μl of the reaction product digested with DpnI enzyme, and transform, and spread the transformed bacteria on a kanamycin-resistant LB plate. Incubate the plate in a 37°C incubator for 16 hours.

[0097] Identification of recombinant plasmid: Pick a single clone colony and inoculate it into 5 ml of kanamycin-resistant LB medium, and culture it at 37°C for 12 hours. Use a plasmid extraction kit (Axygen) to extract a small amount of plasmid DNA. Send it to Shanghai Shenggong Biological Co., Ltd. for DNA sequencing analysis to confirm the correctness of the target gene sequence.

[0098] Example 2 Expression and purification of sphingomyelinase mutants

[0099] The recombinant plasmid was transformed into E. coli BL21 (DE3), and IPTG was added to the culture to induce expression. The induced expressed protein was ultrasonically broken and centrifuged, and the supernatant was subjected to nickel affinity chromatography (Sangon Biotech) and desalting chromatography column (GE) to obtain purified sphingomyelinase mutants. A total of 5 sphingomyelinase mutants were obtained, and their amino acid sequences are shown in SEQ ID NO: 2 to 6.

[0100] The specific steps are as follows:

[0101] (1) The recombinant plasmid containing the point-mutated sphingomyelinase DNA fragment of Example 1 was transformed into E. coli BL21 (DE3). The single clone colony on the plate was picked and inoculated into 5 ml of LB medium, and cultured at 37°C with shaking for 12 h. The entire culture was inoculated into 300 ml of fresh LB medium, and cultured at 37°C with shaking for 3 h. When the bacterial solution OD 600nm When the pH reached 0.6, IPTG was added to the culture at a final concentration of 0.5 mM and culture was continued for 12 h at 20° C. The culture was collected and centrifuged at 4000 rpm for 20 min at 4° C.

[0102] (2) The bacterial precipitate obtained by centrifugation was fully resuspended in buffer A. Ultrasonic disruption was selected. After the bacterial solution became clear, it was centrifuged at 4°C, 13000rpm for 30min, and the supernatant was collected. 1ml Ni-NTA suspension was added to the supernatant, and the mixture was mixed evenly at 4°C on a shaker for 1h. The mixture was added to the chromatography column, and the Ni-NTA matrix was precipitated in the chromatography column. 1 column volume of buffer A was added to the chromatography column, and the chromatography column was washed, and the column was washed four times. 5ml of buffer A containing 20mM imidazole was added to the chromatography column to elute the impurity protein, and the column was repeated three times. Then, 2ml of elution buffer B was added to the chromatography column in portions, and the target protein was eluted and collected in a 1.5ml centrifuge tube. The target protein eluate obtained was centrifuged at 4°C, 13000rpm for 20min, and the supernatant was taken for desalting chromatography using an ATKA protein purifier (GE Company), so that the protein was in buffer C, glycerol was added to 50%, and stored at -80°C. The purified product was assayed.

[0103] The buffer A comprises: 50 mM potassium phosphate, 500 mM NaCl, the remainder being water, and pH 8.0.

[0104] The components of the elution buffer B are: 50 mM potassium phosphate, 500 mM NaCl, 250 mM Imidazole, and the balance is water, pH 8.0.

[0105] The components of the buffer C are: 50 mM Tris-Cl, the balance is water, pH 8.0.

[0106] Example 3 Detection of sphingomyelinase activity

[0107] (1) Detection principle: Sphingomyelinase can hydrolyze sphingomyelin to generate phosphocholine and ceramide. Under alkaline conditions, phosphocholine is hydrolyzed by alkaline phosphatase (ALP enzyme) to produce choline, which is oxidized by choline oxidase (COD enzyme) to generate betaine and H2O2. H2O2 generates red quinone compounds through the Trinder reaction in the presence of N-ethyl-N-(2-hydroxy-3-sulfopropyl)-3-methylaniline sodium salt (TOOS), 4-aminoantipyrine (4-AAT) and peroxidase (POD), which can be measured by absorbance at 555nm. The amount of H2O2 generated can be calculated by the absorbance value, thereby obtaining the activity of sphingomyelinase.

[0108] (2) Definition of enzyme activity: Unit enzyme activity is defined as the amount of enzyme required to catalyze the production of 1 μmol of H2O2 per minute at 37°C.

[0109] The activity of sphingomyelinase was calculated by the following formula:

[0110]

[0111] Where D represents the total dilution factor of the enzyme in the reaction; 39.2 represents the millimolar absorption coefficient (cm) of the chromophore at 555 nm under standard reaction conditions. 2 / μmol); 1 / 2 means that 1 mol H2O2 generates 1 / 2 mol quinone compounds; C represents the concentration of the enzyme (mg / ml).

[0112] The specific steps are as follows: preheat 180 μl of reaction reagent 1 at 30°C, add reaction reagent 2 and 10 μl of the enzyme solution to be tested, mix well, react at 37°C, and use a spectrophotometer to record the absorbance change at 555 nm per minute, i.e., ΔA1.

[0113] Reagent 1 and reagent 2 for determining sphingomyelinase activity are as follows:

[0114] Reagent 1 (freshly prepared): 50 mM Tris-HCl, pH 8.0; 2 mM MgCl2; 1 mM sphingomyelin; 2 mM TOOS; 2 mM 4-AAT; 10 mM NaCl; 0.1% (w / v) Triton X-100; 5 U POD enzyme.

[0115] Reaction reagent 2: 10U ALP enzyme; 10U COD enzyme.

[0116] Blank control: Use 10mM Tris-HCl, pH 8.0, containing 0.1% TritonX-100 and 10mM NaCl to replace the enzyme solution to be tested. The rest of the operation is the same as above. The absorbance change of the blank control is recorded as ΔA2.

[0117] Let ΔA1-ΔA2 be ΔA 555 nm The activity of sphingomyelinase and mutants was calculated by the above formula.

[0118] The results are as follows Figure 1 As shown, the activities of the five mutants were 2 to 3 times higher than that of the wild type.

[0119] Example 4: Determination of sdLDL cholesterol content using sphingomyelinase mutants

[0120] The method of the present invention is to use five sphingomyelinase mutants and wild-type sphingomyelinase to remove cholesterol from lipoproteins other than sdLDL, so as to exclude cholesterol from the reaction system, and then measure the sdLDL cholesterol content. The details are as follows:

[0121] Add reagent A (75 μl) to 2 μl serum sample and react at 37°C for 5 minutes. Add reagent B (75 μl) and react for 5 minutes. Add reagent C (50 μl) and react for 5 minutes. Then measure the absorbance at the main wavelength of 600 nm and the sub-wavelength of 700 nm.

[0122] Control method: The cholesterol content in sdLDL was quantitatively determined using sd LDL-C "SEIKEN" (DENKA SEIKEN) reagent.

[0123] Comparison of sdLDL cholesterol concentrations measured by the two methods, such as Figure 2 As shown, the assay results of the five mutants showed good correlation with the assay results using the sd LDL-C "SEIKEN" reagent.

[0124] Reagent A used in the step of removing cholesterol from lipoproteins other than LDL, reagent B used in the step of removing cholesterol from L LDL, and reagent C used in the step of measuring sdLDL cholesterol are as follows.

[0125] Reagent A: 50 mM PIPES, pH 7.0; 0.6 U / ml cholesterol esterase; 0.5 U / ml cholesterol oxidase; 600 U / ml catalase; 2 mM TOOS; 0.27% (w / v) polyoxyethylene derivative [Kao Company, EMULGEN B-66].

[0126] Reagent B: 50 mM PIPES, pH 7.0; different activity units of sphingomyelinase.

[0127] Reagent C: 50 mM PIPES, pH 7.0; 4 mM 4-AAT; 4 U / ml peroxidase; 0.05% (w / v) sodium azide; 1% (w / v) polyoxyethylene nonylphenyl ether [Kao Company, EMULGEN 909].

[0128] Example 5 Determination of sdLDL cholesterol content in clinical specimens

[0129] Clinical blood or tissue specimens are used as test objects, specimens are collected, and sample testing is performed: the following components are added to the ELISA plate: serum (or plasma) specimen (2ul), reaction reagent A (75μl), reaction reagent B (75μl) and reaction reagent C (50μl). After addition, the reaction program of the ELISA instrument is set: oscillate and mix, and detect the change of absorbance at 600nm and 700nm over time.

[0130] Example 6 Thermal stability analysis of sphingomyelinase mutants

[0131] The thermal stability of sphingomyelinase mutants and wild-type sphingomyelinase was analyzed. After incubating each protein at 4°C, 37°C, 42°C, 50°C, 55°C, 60°C, 65°C, 70°C, 75°C and 80°C for 10 minutes, the sphingomyelinase activity measured before and after incubation was compared, and the residual activity of each protein was calculated.

[0132] The results are as follows Figure 3 As shown, there was almost no loss of activity after incubation at 4°C and 37°C for 10 minutes. Starting from 42°C, the activity of each protein after incubation at a specified temperature for 10 minutes gradually weakened with the increase of temperature, and the protein was almost inactive after incubation at 80°C for 10 minutes. The thermal stability of the five mutants is similar to that of the wild-type protein.

[0133] Example 7 Storage Temperature Stability Analysis of Sphingomyelinase Mutants

[0134] For the storage temperature stability analysis of sphingomyelinase mutants and wild-type sphingomyelinase, each protein stored in 25 mM Tris-Cl, pH 8.0, 50% glycerol buffer was stored at -20°C, 4°C and 25°C, and the sphingomyelinase activity was measured monthly, and the residual activity of each protein was calculated.

[0135] The results are as follows Figure 4 , Figure 5 , Figure 6 As shown. Figure 4 As shown in Figure 2, the five mutants had similar stabilities to the wild-type protein when stored at -20°C. Figure 5 As shown in Figure 2, the five mutants had similar stabilities to the wild-type protein when stored at 4°C. Figure 6 As shown, at 25°C, the storage stability of the four single-point mutants was similar to that of the wild-type protein, and the mutant MUT with simultaneous mutations at four sites had higher storage stability than the wild-type protein.

[0136] The above examples are provided to those skilled in the art to fully disclose and describe how to make and use the claimed embodiments, rather than to limit the scope of the disclosure herein. Modifications that are obvious to those skilled in the art will fall within the scope of the appended claims.

Claims

1. A sphingomyelinase mutant, characterized in that One of the following five: a sphingomyelinase mutant D118Q, whose amino acid sequence is shown in SEQ ID NO: 2; Sphingomyelinase mutant N122D, whose amino acid sequence is shown in SEQ ID NO: 3; a sphingomyelinase mutant N333E, whose amino acid sequence is shown in SEQ ID NO:4; a sphingomyelinase mutant Q376Y, whose amino acid sequence is shown in SEQ ID NO:5; The amino acid sequence of the sphingomyelinase mutant MUT is shown in SEQ ID NO:

6.

2. Use of the sphingomyelinase mutant according to claim 1 in the preparation of an sdLDL cholesterol detection reagent.

3. The use according to claim 2, characterized in that: In specific applications, the sample to be tested is whole blood, plasma, serum or tissue.

4. A gene encoding a sphingomyelinase mutant, characterized in that: One of the following five: A gene encoding a sphingomyelinase mutant D118Q, the nucleotide sequence of which is shown in SEQ ID NO: 8; A gene encoding a sphingomyelinase mutant N122D, the nucleotide sequence of which is shown in SEQ ID NO:9; A gene encoding a sphingomyelinase mutant N333E, the nucleotide sequence of which is shown in SEQ ID NO: 10; A gene encoding a sphingomyelinase mutant Q376Y, the nucleotide sequence of which is shown in SEQ ID NO: 11; The nucleotide sequence of the gene encoding the sphingomyelinase mutant MUT is shown in SEQ ID NO:

12.

5. Use of the gene encoding the sphingomyelinase mutant according to claim 4 in preparing the sphingomyelinase mutant.